GSK in talks with Trump administration on U.S. drug pricing, CEO says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500 near flat as traders shift out of risky AI bets
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mail
FILE PHOTO: A staff member walks down stairs in the main lobby of GSK offices in London, Britain, February 20, 2025. REUTERS/Chris J. Ratcliffe/File Photo
LONDON (Reuters) -British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, becoming the latest pharmaceutical company to acknowledge action under pressure from Washington to rein in prices.
GSK CEO Emma Walmsley said on a call with journalists after the company posted second-quarter profits above analyst expectations that the discussions with the U.S. administration are "about how to make sure discounts are passed on to patients and pricing is sustainable, both for the government and also for industry."
(Reporting by Pushkala Aripaka and Maggie Fick, Editing by Louise Heavens)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Brazil candidates focus fiscal plans on voter-friendly measures before runoff
- US Justice Dept sues California to block votes from alleged noncitizens
- Italy's UniCredit wins ECB approval to control Germany's Commerzbank
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
